Fig. 5: RNT studies using 131I-nanobots in a bladder cancer orthotopic murine model.
From: Urease-powered nanobots for radionuclide bladder cancer therapy
a, Schematic representation and timeline of the RNT studies. b, Changes in body weight over time, showing mean and s.e.m. (n = 9 per group, except n = 13 for nanobots in urea and n = 7 for high-dose (HD) 131I-nanobots in water and urea, biological replicates). LD, low-dose. c, DW-MRI 2D slices through the bladder of tumour-bearing mice before and after treatment with radionuclides; low-dose (LD) and high-dose (HD) denote 1.85 MBq and 18.5 MBq doses of 131I, respectively; yellow dotted lines show the bladders. Scale bars, 2 mm. d, NTV obtained by MRI before and after treatment. Tumour volumes were normalized by the means of the pretreatment values of each group (n = 9 per group, except n = 13 for nanobots in urea and n = 7 for high-dose 131I-nanobots in water and urea, biological replicates). Data are presented as mean values and error bars represent the s.e.m. Statistical significances are based on a two-tailed unpaired t-test. Inset: tumour volume changes with respect to pretreatment (see e for legend). e, Post-treatment tumour volumes normalized to control condition (non-treated group). Panel a created with BioRender.com.
